Real-life effectiveness of budesonide/formoterol maintenance and reliever therapy in asthma patients across Asia: SMARTASIA study

Nanshan Zhong, Jiangtao Lin, Parthiv Mehta, Pintip Ngamjanyaporn, Tzu-Chin Wu, Faisal Yunus, Nanshan Zhong, Jiangtao Lin, Parthiv Mehta, Pintip Ngamjanyaporn, Tzu-Chin Wu, Faisal Yunus

Abstract

Background: The use of budesonide/formoterol in a single inhaler for both maintenance and reliever therapy is a recommended option for treatment of persistent asthma not responding well to inhaled corticosteroid (ICS) alone.

Methods: This was a multi-centre open-label study on patients whose asthma condition remained inadequately controlled by various asthma treatments other than budesonide/formoterol. After a 2-week run-in period, eligible patients underwent a 12-week treatment period with budesonide/formoterol (Symbicort SMART(®), 160/4.5 μg) twice daily plus as needed. Patient's asthma control and quality of life were assessed using the 5-item Asthma Control Questionnaire (ACQ-5) and the standardized Asthma Quality of Life Questionnaire (AQLQ-S), respectively.

Results: A total of 862 eligible asthma patients who have had asthma for a mean duration of 10.73 ± 12.03 years entered a 12-week treatment with budesonide/formoterol maintenance and reliever therapy. During treatment, ACQ-5 score improved significantly by 0.58 ± 0.93 (95% CI, 0.51 to 0.64, P < 0.0001) from the baseline level of 1.62 ± 1.00. AQLQ(S) score improved by 0.70 ± 0.89 (95% CI, 0.64 to 0.76, P < 0.0001) from baseline. Asthma symptom score was also reduced significantly (P < 0.0001); between run-in and treatment periods, night- and day-time symptom scores were reduced by 0.32 ± 0.54 (95% CI, 0.28 to 0.35) and 0.30 ± 0.52 (95% CI, 0.27 to 0.34), respectively. The percentage of nights with awakenings due to asthma symptoms was reduced by 11.09 ± 26.13% (95% CI, 9.34 to 12.85%), while the percentage of asthma-control and symptom-free days increased by 20.90 ± 34.40% (95% CI, 18.59 to 23.21%) and 23.89 ± 34.62% (95% CI, 21.56 to 26.21%), respectively (P < 0.0001). Together with the improvement in asthma control, the number of night- and day-time inhalations of as-needed reliever medication decreased by 0.30 ± 0.82 (95% CI, 0.24 to 0.35) inhalations and 0.30 ± 0.97 (95% CI, 0.23 to 0.36) inhalations, respectively (P < 0.0001). No unexpected adverse events were reported.

Conclusion: During treatment of inadequately controlled asthmatic patients with budesonide/formoterol maintenance and reliever therapy, significant improvement in patients' asthma control and reductions in asthma symptoms and as-needed medication use was observed. Patients' quality of life was improved and the treatment was well tolerated.

Trial registration: ClinicalTrial.gov: (NCT00939341).

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
Mean ACQ-5 scores following initiation of treatment with budesonide/formoterol maintenance and reliever therapy (regional level). * denotes significant difference from baseline level. Visit 2 = baseline.
Figure 3
Figure 3
Mean Change in ACQ-5 scores from baseline to treatment period (by country/area). * denotes significant difference from baseline level.
Figure 4
Figure 4
G-mean FEV1 change from Visit 2 (baseline) and 95% CI.

References

    1. Montuschi P. Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues. Front Pharmacol. 2011;2:35.
    1. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292(3):367–376. doi: 10.1001/jama.292.3.367.
    1. Paris J, Peterson EL, Wells K, Pladevall M, Burchard EG, Choudhry S, Lanfear DE, Williams LK. Relationship between recent short-acting beta-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol. 2008;101(5):482–487. doi: 10.1016/S1081-1206(10)60286-4.
    1. Mintz M, Gilsenan AW, Bui CL, Ziemiecki R, Stanford RH, Lincourt W, Ortega H. Assessment of asthma control in primary care. Curr Med Res Opin. 2009;25:2523–2531. doi: 10.1185/03007990903218655.
    1. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, Weiss ST. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114:40–47. doi: 10.1016/j.jaci.2004.04.042.
    1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2010. Available from: (accessed October 2011)
    1. British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline. Available at: 2010 [accessed October 2010]
    1. Postma DS, Kerstjens HA, ten Hacken NH. Inhaled corticosteroids and long-acting beta-agonists in adult asthma: a winning combination in all? Naunyn Schmiedebergs Arch Pharmacol. 2008;378(2):203–215. doi: 10.1007/s00210-008-0302-y.
    1. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet. 2006;368:744–753. doi: 10.1016/S0140-6736(06)69284-2.
    1. Rabe KF, Pizzichini E, Ställberg B, Romero S, Balanzat AM, Atienza T, Lier PA, Jorup C. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006;129:246–256. doi: 10.1378/chest.129.2.246.
    1. Zetterström O, Buhl R, Mellem H, Perpiñá M, Hedman J, O’Neill S, Ekström T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001;18:262–268. doi: 10.1183/09031936.01.00065801.
    1. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O’Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405–1411. doi: 10.1056/NEJM199711133372001.
    1. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer A. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101:2437–2446. doi: 10.1016/j.rmed.2007.07.014.
    1. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin. 2004;20:1403–1418. doi: 10.1185/030079904X2051.
    1. Bateman ED, Harrison TW, Quirce S, Reddel HK, Buhl R, Humbert M, Jenkins CR, Peterson S, Ostlund O, O’Byrne PM, Sears MR, Eriksson GS. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011;12:38. doi: 10.1186/1465-9921-12-38.
    1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2007. Available from: (accessed April, 2013)
    1. Juniper EF, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi: 10.1034/j.1399-3003.1999.14d29.x.
    1. Juniper EF, As B, Cox FM, Ferrie PJ, King DR. Validation of a standardised version of the Asthma Quality of Life Questionnaire. Chest. 1999;115:1265–1270. doi: 10.1378/chest.115.5.1265.
    1. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the asthma quality of life questionnaire. Chest. 1999;115(5):1265–1270. doi: 10.1378/chest.115.5.1265.
    1. Juniper EF, Stahl E, O’Byrne PM. Minimal important difference for the asthma control questionnaire. Resp Crit Care Med. 2001;163(5):A642.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805.
    1. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(suppl. 16):5–40.
    1. Louis R, Joos G, Michils A, Vandenhoven G. A comparison of budesonide/formoterol maintenance and reliever therapy vs. conventional best practice in asthma management. Int J Clin Pract. 2009;63(10):1479–1488. doi: 10.1111/j.1742-1241.2009.02185.x.
    1. Ni Chroinin M, Greenstone IR, Danish A, Magdolinos H, Masse V, Zhang X, Ducharme FM. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst Rev. 2005;9(4):CD005535. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005535.
    1. Frois C, Wu EQ, Ray S, Colice GL. Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol. Clin Ther. 2009;31(12):2779–2803. doi: 10.1016/j.clinthera.2009.12.021.
    1. Buhl R, Vogelmeier C. Budesonide/formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin. 2007;23(8):1867–1878. doi: 10.1185/030079907X210769.
    1. Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev. 2010;19(4):CD005533. Review. Update in: Cochrane Database Syst Rev. 2010;(4):CD005533.
    1. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med. 2009;103:1960–1968. doi: 10.1016/j.rmed.2009.08.007.
    1. Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev. 2010;1:CD007694.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren